We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
One More Step to Finalize Your Registration
An activation link has been sent to your email address.
Please check the email and activate your account now. It might take few minutes to get the email.
If you did not find it, please check your spam box.
Having problem receiving the email? Send again
Still cannot receive? Contact us
Email ：PharmaSources@imsinoexpo.com
Whatsapp ：+86-13621645194
Main Sales Markets: North America,Central/South America,Western Europe,Eastern Europe,Australasia,Eastern Europe,Australasia,Asia,Middle East,Africa
Sample Provided: no
【 Main ingredient 】 Lincomycin hydrochloride
[Sex] This product is colorless to yellowish or yellowish green clear liquid.
【 Pharmacological action 】 Pharmacodynamics Lincomycin is a lincomamine antibiotic, a bacteriostatic agent, Sensitive bacteria include Staphylococcus aureus (including penicillin-resistant strains), Streptococcus, pneumococcus, Bacillus anthracis, Erysipelas suis, certain mycoplasma (mycoplasma suis pneumoniae, mycoplasma suis nasal, mycoplasma suis synovialis), leptospirosis and anaerobic bacteria (such as clostridium difficile, Clostridium tetanus, percapsular bacteria and actinomyces). It mainly acts on the 50S subunit of the bacterial ribosome, and plays an antibacterial role by inhibiting the extension of the peptide chain and affecting the synthesis of proteins.
Pharmacokinetic absorption was rapid after intramuscular injection, with a single intramuscular injection of 11mg/kg and a peak blood concentration of 6.25μg/ml. The plasma protein binding rate was 57%-72%. It is widely distributed in vivo, with an apparent distribution volume of 2.8L/kg in pigs. It is widely distributed in various body fluids and tissues (including bone), among which the concentration of liver and kidney is the highest, and the concentration of tissue drug is several times higher than that of serum in the same period. It can enter the placenta, but it is not easy to cross the blood-brain barrier, and it is difficult to reach an effective concentration in the cerebrospinal fluid during inflammation. It can be distributed to milk, and the concentration in milk is the same as that in plasma. Some drugs are metabolized in the liver, and the drug form and its metabolites are excreted through bile, urine and milk. Fecal excretion can be delayed for several days, so it has an inhibitory effect on intestinal sensitive microorganisms.
【 Drug interaction 】
(1) When combined with gentamicin, it has a synergistic effect on gram-positive bacteria such as staphylococcus and streptococcus.
(2) Combined with aminoglycosides and polypeptide antibiotics, it may enhance the blocking effect on the neuromuscular junction. In combination with erythromycin, it has antagonistic effect because of the same site of action and the affinity ratio of erythromycin to the 50S subunit of bacterial ribosomes
This product is strong.
(3) It should not be combined with anti-diarrheal drugs that inhibit intestinal peristalsis and contain white clay.
(4) There is incompatibility with kanamycin and neomycin.
【 Function and use 】 Lincoamine antibiotics. For Gram-positive infections,
It can also be used for infections such as treponemosis and mycoplasma.
[Usage and dosage] Intramuscular injection: one dose, 0.033ml per 1kg body weight, once a day; For dogs and cats, 0.033ml is used twice a day for 3-5 days.
[Adverse reaction] has neuromuscular blocking effect.
[Precautions] Intramuscular administration may cause transient diarrhea or soft stools. Although rare, necessary measures should be taken to prevent dehydration if it does occur.
【 Drug withdrawal period 】 Pig 2 days.
[Grid] 100ml according to C18H34N2O6S: 30g
[Packing] 100ml/ bottle, 60 bottles/box
【 Storage 】 Sealed storage.
[Approval number] Veterinary Medicine 170611769
【 Manufacturer 】 Wuhan Liyao Pharmaceutical Co., LTD. (Sino-Foreign joint venture)
Audited Supplier
Pharma Sources Insight JANUARY 2024
